GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Bijoy Hans Ltd (BOM:524723) » Definitions » Gross Margin %

Bijoy Hans (BOM:524723) Gross Margin % : 23.59% (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Bijoy Hans Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Bijoy Hans's Gross Profit for the three months ended in Mar. 2024 was ₹0.17 Mil. Bijoy Hans's Revenue for the three months ended in Mar. 2024 was ₹0.71 Mil. Therefore, Bijoy Hans's Gross Margin % for the quarter that ended in Mar. 2024 was 23.59%.

Warning Sign:

Bijoy Hans Ltd gross margin has been in long-term decline. The average rate of decline per year is -8.1%.


The historical rank and industry rank for Bijoy Hans's Gross Margin % or its related term are showing as below:

BOM:524723' s Gross Margin % Range Over the Past 10 Years
Min: 14.08   Med: 29.7   Max: 36.64
Current: 23.27


During the past 13 years, the highest Gross Margin % of Bijoy Hans was 36.64%. The lowest was 14.08%. And the median was 29.70%.

BOM:524723's Gross Margin % is ranked better than
62.5% of 96 companies
in the Medical Distribution industry
Industry Median: 16.365 vs BOM:524723: 23.27

Bijoy Hans had a gross margin of 23.59% for the quarter that ended in Mar. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Bijoy Hans was -8.10% per year.


Bijoy Hans Gross Margin % Historical Data

The historical data trend for Bijoy Hans's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bijoy Hans Gross Margin % Chart

Bijoy Hans Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.11 26.82 29.02 27.34 23.27

Bijoy Hans Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.66 21.82 24.10 23.53 23.59

Competitive Comparison of Bijoy Hans's Gross Margin %

For the Medical Distribution subindustry, Bijoy Hans's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bijoy Hans's Gross Margin % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Bijoy Hans's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bijoy Hans's Gross Margin % falls into.



Bijoy Hans Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bijoy Hans's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=0.7 / 2.798
=(Revenue - Cost of Goods Sold) / Revenue
=(2.798 - 2.147) / 2.798
=23.27 %

Bijoy Hans's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.2 / 0.708
=(Revenue - Cost of Goods Sold) / Revenue
=(0.708 - 0.541) / 0.708
=23.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Bijoy Hans  (BOM:524723) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bijoy Hans had a gross margin of 23.59% for the quarter that ended in Mar. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Bijoy Hans Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bijoy Hans's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bijoy Hans (BOM:524723) Business Description

Traded in Other Exchanges
N/A
Address
H P Brahmachari Road, Rehabari, Guwahati, AS, IND, 781008
Bijoy Hans Ltd is engaged in the business activity of wholesale pharmaceuticals, medical goods, and cosmetics. The company offers various pharmaceutical formulations such as tablets, capsules, syrups, suspensions, and powders, focusing on segments such as antibiotics, cough/cold/allergy, h-1 receptor antagonists, and NSAIDs.

Bijoy Hans (BOM:524723) Headlines

No Headlines